| Date | Title | Description | Source |
| 11.04.2024 | Nuevocor Strengthens Leadership Team with Appointment of Joh... | SINGAPORE and PHILADELPHIA, April 11, 2024 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnol... | en.prnasia... |
| 30.11.2021 | Slone Partners Places Jonathan Birchall as Chief Commercial ... | “Jonathan Birchall is a respected leader with a history of building highly successful commercial ope... | prweb.com/... |
| 22.06.2021 | Alfasigma acquires the European license for bentracimab from... | BOLOGNA, Italy, 22 giugno 2021 /PRNewswire/ -- Alfasigma has entered into an exclusive licensing agr... | en.prnasia... |
| 15.03.2021 | PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial... | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 15, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq... | oaoa.com/n... |
| 11.03.2021 | PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agr... | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 11, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq... | oaoa.com/n... |
| 19.10.2018 | PhaseBio goes public in downsized offering of $46 million | On Sept. 5, the company announced the closure of a Series D financing round worth $34 million, with ... | medcitynew... |
| 05.09.2018 | PhaseBio Secures $34M in Series D Financing | PhaseBio Pharmaceuticals, Inc., a Malvern, PA-based clinical-stage biopharmaceutical company focused... | finsmes.co... |
| 05.09.2018 | PhaseBio Secures $34 Million in Series D Financing | MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage bi... | citybizlis... |
| 05.09.2018 | PhaseBio nets $34M to advance Brilinta reversal agent, PAH d... | PhaseBio raised $34 million in its series D round, which will advance its lead assets: a treatment f... | fiercebiot... |
| 05.09.2018 | PhaseBio nets $34M to advance Brilinta reversal agent, PAH d... | PhaseBio raised $34 million in its series D round, which will advance its lead assets: a treatment f... | fiercebiot... |
| 09.03.2018 | Outsourcing veteran Jamie Macdonald takes the helm at ... | Josef von Rickenbach
→ Top-10 CRO Parexel has brought in an experienced hand to take the helm.... | endpts.com... |
| 30.11.2017 | PhaseBio Pharmaceuticals Secures $15.6m in Funding | PhaseBio Pharmaceuticals, Inc., a Malvern, PA-based clinical-stage biopharmaceutical company develop... | finsmes.co... |
| 29.11.2017 | J&J disputes report it’s dropping JLabs plans for UK;... | → The Telegraph reported that J&J is planning to pull the plug on its plans to open a JLabs ... | endpts.com... |
| 12.03.2015 | PhaseBio Pharmaceuticals Secures $40M in Series C Funding | PhaseBio Pharmaceuticals Inc., a Malvern, Pennsylvania-based company focused on developing treatment... | finsmes.co... |
| 12.03.2015 | PhaseBio Raises $40 Million Series C Financing | - | jnjinnovat... |
| 21.08.2012 | Type 2 diabetes drug with goal of 24/7 glycemic control begi... | The biotechnology firm raised $48.4 million earlier this year in its third tranche for its series B ... | medcitynew... |
| 06.06.2012 | Hyperglycemia drug developer raises $25 million to advance p... | Prior added that the results of its long-acting drug for hyperglycemia were so compelling it wants t... | medcitynew... |
| 05.06.2012 | PhaseBio Pharma Receives Additional $23M |
MALVERN, PA, Clinical-stage biotechnology company developing drugs to treat diabetes, metabolic di... | vcnewsdail... |
| 05.06.2012 | PhaseBio Pharmaceuticals Received an Additional $23 Million ... | - | jnjinnovat... |
| 15.11.2011 | Hyperglycemia drug gets positive results in clinical trial | GLP-1 analogues that have been approved by the U.S. Food and Drug Administration need to be given at... | medcitynew... |
| 03.12.2010 | Diabetes, cardiovascular drug developer PhaseBio adds $15M | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently... | medcitynew... |
| 02.12.2010 | PhaseBio Pharmaceuticals Raises $15M in Series B Financing | PhaseBio Pharmaceuticals, Inc., a Malvern, Pennsylvania-based clinical-stage biotechnology company d... | finsmes.co... |
| 07.01.2010 | PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series ... | - | jnjinnovat... |
| 07.01.2010 | PhaseBio Pharmaceuticals Raises $25M in Series B Funding Rou... | PhaseBio Pharmaceuticals, Inc., a Research Triangle Park, NC-based company focusing on the discovery... | finsmes.co... |
| - | Hyperglycemia drug developer raises $25 million to advance p... | A biotechnology company developing a long-acting drug and insulin to treat hyperglycemia in people w... | medcitynew... |
| - | PhaseBio Announces Pricing of Public Offering of Common Stoc... | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 17, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq... | oaoa.com/n... |
| - | PhaseBio Announces Proposed Public Offering of Common Stock | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 17, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq... | oaoa.com/n... |
| - | Type 2 diabetes drug with goal of 24/7 glycemic control begi... | A biotechnology company developing a long-acting drug for hyperglycemia associated with type 2 diabe... | medcitynew... |
| - | PhaseBio goes public in downsized offering of $46 million | A biotechnology company developing therapies for pulmonary arterial hypertension and for bleeding in... | medcitynew... |
| - | Diabetes, cardiovascular drug developer PhaseBio adds $15M | The Philadelphia-area biopharma company PhaseBio Pharmaceuticals has received the final $15 million ... | medcitynew... |
| - | Hyperglycemia drug gets positive results in clinical trial | PhaseBio Pharmaceuticals‘ phase I/IIa clinical study for its drug, Glymera, for the treatment of hyp... | medcitynew... |
| - | PhaseBio Pharmaceuticals to Host Virtual Investor and Analys... | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Feb 24, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq... | oaoa.com/n... |
